The competitive landscape analysis shows "Curaleaf stock forecast 2025" outperforming peer averages in projected store productivity metrics. With capex discipline holding steady, fair value estimates are adjusted upward by 6%. for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor . North America was the largest region in the cannabis pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. Year-end 2024 liquidity ratios underpin a stable "Curaleaf stock forecast 2025", with current assets exceeding liabilities by 1.4x. This balance sheet strength supports forecasts targeting sustainable mid-single-digit EBITDA growth rates.